title: Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
abstract: Low dose-ritonavir boosted protease inhibitors are increasingly being used for the first-line antiretroviral treatment, though their virological efficacy has just poorly been compared to alternative antiretroviral therapies. Here, we retrospectively investigated the virological responses of 316 protease inhibitor-naive HIV patients receiving highly active antiretroviral treatment based on a single (n = 256) or a ritonavir-boosted protease inhibitor (n = 60), both in the background of two nucleoside analogues. - By intent-to-treat analysis, a complete initial virological response was achieved in 71.8% of all patients in the single protease inhibitor group (indinavir: 76%, ritonavir: 67.5%, nelfinavir: 70.6%) and in 88.3% (p = 0.008) of patients treated with a boosted protease inhibitor (saquinavir/r: 71.4%, indinavir/r: 92.1%, lopinavir/r: 86.6%). The multivariate risk analysis identified boosted PI treatment as an independent predictor of a complete virological response (OR = 2.8, p=0.02). Viral rebound after an initial complete virological response was observed in 28% and 17% (p = 0.06) of patients receiving a single or a dual protease inhibitor, respectively. The rate of durable viral suppression over 12 months was 44.5% and 56.7% (p = 0.09) in the respective study cohorts. Ritonavir-boosted protease inhibitors therefore seem to induce a superior virological response rate and a higher degree of sustained virological suppression.
authors.affiliation: Department of General Internal Medicine, Rheinische Friedrich Wilhems Universität Bonn, Bonn, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Lichterfeld
authors.forename: A
authors.initials: A
authors.lastname: Wöhrmann
authors.forename: N
authors.initials: N
authors.lastname: Schmeisser
authors.forename: G
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: B
authors.initials: B
authors.lastname: Salzberger
authors.forename: C
authors.initials: C
authors.lastname: Wyen
authors.forename: K
authors.initials: K
authors.lastname: Schmitz
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019438:Ritonavir